(Press-News.org) The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic—an effective antiviral that has since successfully treated millions. But like many antivirals before it, scientists know that at some point, Paxlovid is likely to lose some efficacy due to drug resistance. Researchers working to stay ahead of such emerging threats have now identified a wholly new way to treat SARS-CoV-2 infections—work that may have even broader implications.
In fact, a new study by the Tuschl laboratory introduces a proof-of-concept for a novel class of antivirals that would target a type of enzyme essential not just to SARS, but also many RNA viruses, including Ebola and dengue, as well as cytosolic-replicating DNA viruses, including Pox viruses. The findings may pave the way for a faster and more robust response to future pandemics. “Nobody has found a way to inhibit this enzyme before,” says Thomas Tuschl, the F. M. Al Akl and Margaret Al Akl professor at Rockefeller. “Our work establishes cap methyl transferase enzymes as therapeutic targets and opens the door to many more antiviral developments against pathogens that until now we’ve had only limited tools to fight.”
A new way forward
The way so many RNA viruses thrive is by modifying their RNA caps, specialized structures that stabilize viral RNA, enhance its translation, and mimic host mRNA to evade immune defenses. RNA capping relies on enzymes called methyltransferases—making it a tempting target for antiviral therapies.
But most antivirals, including Paxlovid, instead focus on disrupting proteases, a different class of viral enzymes that break down proteins—largely because those enzymes were previously targeted and prevented viral spread. "Inhibiting methyltransferase required using a non-conventional RNA substrate adding a new challenge to drug to discovery," Tuschl says.
For Tuschl, an RNA expert whose work has already led to multiple RNA therapeutics for treatment of genetic disorders, that was not much of a complication. And after he restructured his lab during the pandemic to focus on antiviral drug discovery, Tuschl realized there were clear advantages to looking beyond protease inhibitors. Tuschl suspected that viruses would be less likely to dodge a combination therapy that targeted two unrelated viral enzymes at once, such as a protease inhibitor alongside a methyltransferase inhibitor. He also realized that drugs targeting viral methyltransferase distinct in structure from the human enzyme will be highly selective and not impair human enzyme function.
In search of a molecule capable of inhibiting the SARS-CoV-2 methyltransferase NSP14, his team screened 430,000 compounds early in the pandemic in the university’s Fisher Drug Discovery Resource Center and discovered a small number of compounds that inhibited the viral cap methyltransferase NSP14, a multifunctional enzyme with methyltransferase activity.
Those compounds then went through an extensive chemical developmental process to create optimized drug candidates in partnership with the Sanders Tri-Institutional Therapeutics Discovery Institute. Compounds with improved biochemical inhibition were then subjected to cell-based assays conducted by researchers led by Charles M. Rice, who heads the Laboratory of Virology and Infectious Disease at Rockefeller. Finally, colleagues at the Center for Discovery and Innovation in New Jersey then tested the compound in mice under BL3 safety conditions and demonstrated that it could treat COVID-19 on par with Paxlovid. Tuschl and colleagues also demonstrated that the treatment remained effective even if the virus mutated in response to it, and that there was synergy when combined with protease inhibitors.
"Even in isolation, a virus would have trouble escaping this compound," Tuschl says. "But as a combined therapy along with a protease inhibitor—escape would be almost impossible."
Back to basics
The findings not only validate viral methyltransferases as promising therapeutic target, but also suggest that Tuschl’s particular inhibitor would have minimal side effects. “The mechanism by which the drug acts is unique,” he notes. In fact, the compound takes advantage of the unique structural features of the viral methyltransferase also requiring the presence of the reaction product of the methyl donor SAM, meaning that the lab’s compound selectively targets the virus without disrupting human processes.
"We're not ready to test the compound in humans," Tuschl cautions. An ideal clinical candidate needs improved stability, bioavailability, and a series of other pharmacologic properties that remain to be optimized in the long-term. "We're an academic lab. For that, we'd need an industry partner."
In the immediate future, the Tuschl lab is expanding this work to explore inhibitors for RSV, flaviviruses, such as dengue and Zika, as well as mpox and even fungal infections, which all share a similar enzymatic vulnerability. "This work opens the door to targeting many pathogens," he says. "It’s a new opportunity to prepare for future pandemics."
END
A new class of antivirals could help prevent future pandemics
2024-12-11
ELSE PRESS RELEASES FROM THIS DATE:
Nature Biotechnology | Generative chemistry enables Insilico to develop gut-restricted PhD inhibitors promising for intestinal mucosal barrier repair and immunomodulation
2024-12-11
The study presents the journey of designing and optimizing novel gut-restricted PHD inhibitors using the comprehensive generative chemistry engine Chemistry42.
From initiation to preclinical candidate nomination, the program spanned only 12 months, during which approximately 115 molecules were synthesized and screened.
Preclinical studies demonstrate ISM5411 to be gut-restricted and PHD-specific, thus reducing cardiovascular and systematical tumorigenic risks.
Two Phase 1 clinical trials of ISM5411 for IBD are currently being conducted in parallel in Australia and China, with the last subject out in both ...
2 U-M faculty members elected to National Academy of Inventors
2024-12-11
ANN ARBOR—Two University of Michigan faculty members have been elected to the National Academy of Inventors, the highest professional distinction awarded solely to inventors.
Robert Bartlett, professor emeritus of surgery at the Medical School, and Zhen Xu, professor of biomedical engineering at the College of Engineering and professor of radiology and neurosurgery at the Medical School, were elected this month to the academy.
Bartlett and Xu were nominated for being innovative researchers with extensive work translating discoveries into ...
Breakthroughs in cell-penetrating monoclonal antibody therapies
2024-12-11
“Monoclonal antibodies (mAb) have emerged as a promising tool in advancing personalized medicine.”
BUFFALO, NY – December 11, 2024 – A news feature on the research paper “Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition” by Rackear et al. was published in Oncotarget’s Volume 15 on November 22, 2024, titled “Advancements in cell-penetrating monoclonal antibody treatment.“
This new publication by Sai Pallavi Pradeep and Raman Bahal from the Department of Pharmaceutical Sciences at the University of Connecticut highlights significant advancements in ...
Accelerated aging in young sickle cell patients linked to elevated T-cell p16INK4a
2024-12-11
“These initial results suggest that individuals with SCD have a significantly higher cellular senescence burden which may contribute to premature aging, physiological decline, and excess morbidities.”
BUFFALO, NY- December 11, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 16, Issue 21 on November 14, 2024, entitled, “Adolescents and young adults with sickle cell disease exhibit accelerated aging with elevated T-cell p16INK4a expression.”
Researchers Samuel R. Wilson, Natalia Mitin, ...
Nanofluidic devices redefining matter manipulation at an unprecedented level
2024-12-11
One of the great ambitions in the scientific world is to use tiny objects—such as molecules, viruses, and nanoparticles—as building blocks to construct essential macromolecules and materials, much like constructing intricate designs with LEGO bricks. However, achieving this requires overcoming significant challenges. Molecules in liquid environments move randomly and at extraordinary speeds—approximately many times faster than Usain Bolt at peak velocity—making precise manipulation extraordinarily challenging.
To ...
Powering the future together – Public-Private Collaboration for the energy transition in Finland
2024-12-11
Advancing the energy transition requires more than just technological innovation – it demands a joint effort between public and private actors. Giovanna Pinilla De La Cruz’s doctoral dissertation at the University of Vaasa, Finland, explores the mechanisms that foster collaboration in the energy sector, highlighting the Vaasa region’s energy cluster as a successful example.
The transition to sustainable energy systems is one of the most pressing challenges of our time. Successfully navigating this transition requires coordinated ...
Exosome-mediated crosstalk in the tumor immune microenvironment: Critical drivers of hepatocellular carcinoma progression
2024-12-11
The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME attempts to eliminate abnormal cells through immune surveillance. However, as tumors evolve, they exploit the TIME to evade immune responses and promote tumor progression. Exosomes play a central role in this transformation by transporting bioactive molecules such as proteins, lipids, and nucleic acids, thereby influencing processes like immune escape, angiogenesis, and metastasis.
HCC is particularly adept ...
JMIR Aging achieves top ranking, accepted into prestigious science citation indexes
2024-12-11
(Toronto, December 11, 2024) JMIR Publications is proud to announce that JMIR Aging has been accepted for inclusion in the Science Citation Index Expanded (SCIE) and the Social Sciences Citation Index (SSCI).
This accomplishment follows a selective re-evaluation process, where a limited number of Emerging Sources Citation Index (ESCI) journals were considered for inclusion. To be eligible, journals needed to rank among the top three in their respective categories based on the latest Journal Citation Reports (JCR) data. JMIR Aging’s acceptance into SCIE and SSCI underscores its exceptional quality and impact, demonstrated by its outstanding performance ...
Persistent tobacco smoking from childhood may cause heart damage by the mid-twenties
2024-12-11
The majority of children who started smoking tobacco at age 10 years or in their later teens continued to smoke until their mid-twenties. Continuous smoking from childhood significantly increased the risk of premature heart damage, a new study shows. The study was conducted in collaboration between the Universities of Bristol and Exeter in the UK, and the University of Eastern Finland, and the results were published in the prestigious Journal of the American College of Cardiology (JACC).
In the present study, 1,931 children drawn from the University of Bristol’s Children of the 90s cohort were followed up from age 10 until 24 years. ...
Smoking tobacco from childhood can cause premature heart damage
2024-12-11
Cigarette smoking from childhood into early adulthood is associated with an increased risk of premature cardiac injury, according to a study published today in JACC, the flagship journal of the American College of Cardiology. This early damage to the structure and function of the heart can also significantly increase the chance of future cardiovascular (CVD) mortality in mid-life.
“Our goal is to provide data for policymakers, clinicians, and public health practitioners on crucial timing for preventing smoking and its early consequences in youth,” ...